You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
金斯瑞生物科技(01548.HK)公佈中期業績 研發開支增加51.6% 將積極在全球建立產能
格隆匯 08-23 23:35

格隆匯8月23日丨金斯瑞生物科技(01548.HK)發佈公吿,截至2021年6月30日止六個月,集團的收益約為2.3億美元,同比增加38.0%,其中非細胞療法業務的外部收益約為1.96億美元,同比增加36.6%,細胞療法業務的收益約為3390萬美元,同比增加46.8%。

集團的毛利約為1.39億美元,同比增加28.1%,其中非細胞療法業務的毛利約為1.05億美元,同比增加23.0%,細胞療法業務的毛利約為3390萬美元,同比增加46.8%。

於報吿期內,集團大量投入研發活動及人才招聘,兩者均是業務長期可持續增長的主要推動因素。截至2021年6月30日止六個月,集團的研發開支約為1.75億美元,同比增加51.6%,其中期間用於細胞療法的總研發投入約為1.545億美元,同比增加52.1%。

集團的業務營運覆蓋全球逾100個國家,法人實體遍及美國、中國內地、香港、日本、新加坡、荷蘭、愛爾蘭、英國及比利時。截至2021年6月30日,公司的專業團隊僱員數目已增加至約4,558名。

公司表示,集團計劃積極在全球建立產能,以滿足其捕捉到的強勁客户需求。就生命科學服務及產品而言,集團計劃繼續投資升級與擴大中國及美國的自動化基因合成及相關分子生物學產能,擴大中國多肽及寡核苷酸合成能力,在新加坡建立蛋白質及細胞工程設施,並在中國建立GCT供應鏈關鍵試劑及設備的GMP級產能。

就生物製劑開發服務而言,集團計劃擴大中國抗體發現、工藝開發及GMP製造能力,並在中國及美國建立更多GMP製造設施用於質粒及病毒生產。集團亦計劃投資升級供應鏈與IT基礎設施以及其他配套設施,以提高運營效率並適應公司預計的快速業務增長。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account